SCHEMBL16701583

SCHEMBL16701583

C=C(C#N)C(=O)N(CCn1nc(-c2ccc(OC)c(O)c2)c2c(N)ncnc21)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 17/20 0.57
EGFR P00533 16/20 0.57
ABL1 P00519 15/20 0.57
HCK P08631 15/20 0.57
SRC P12931 15/20 0.57
PIK3CA P42336 15/20 0.57
PIK3CB P42338 15/20 0.57
MTOR P42345 15/20 0.57
PIK3CG P48736 15/20 0.57
EPHB4 P54760 15/20 0.57
PRKDC P78527 15/20 0.57
KDR P35968 14/20 0.57
PI4KB Q9UBF8 12/20 0.57
BTK Q06187 3/20 0.48
LCK P06239 1/20 0.47
JAK3 P52333 1/20 0.47
ITK Q08881 1/20 0.47
FGFR1 P11362 1/20 0.46
FGFR2 P21802 1/20 0.46
FGFR3 P22607 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16701837 0.94 SRC (0.49) PIK3CDEGFRABL1HCKSRC
SCHEMBL16702142 0.94 PIK3CD (0.54) PIK3CDEGFRABL1HCKSRC
SCHEMBL16701836 0.92 PIK3CD (0.47) PIK3CDEGFRABL1HCKSRC
SCHEMBL16702030 0.92 PIK3CD (0.55) PIK3CDEGFRABL1HCKSRC
SCHEMBL16701619 0.91 ABL1 (0.57) PIK3CDEGFRABL1HCKSRC
SCHEMBL16701539 0.91 PIK3CA (0.49) PIK3CDEGFRABL1HCKSRC
SCHEMBL16702045 0.91 ABL1 (0.47) PIK3CDEGFRABL1HCKSRC
SCHEMBL16702259 0.90 PIK3CA (0.49) PIK3CDEGFRABL1HCKSRC
SCHEMBL16701657 0.89 PIK3CD (0.60) PIK3CDEGFRABL1HCKSRC
SCHEMBL16702205 0.89 PIK3CA (0.51) PIK3CDEGFRABL1HCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US claimed
WO-2015069441-A1 PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-14 WO claimed
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US disclosed
WO-2015069441-A1 PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272645-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB PIK3CD 2/4885EGFR 828/4885ABL1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.